Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506044 | 0.78 | ADORA2A (0.38) | PTGS2ALDH1A1LMNA | |
| SCHEMBL506398 | 0.75 | PTGS2 (0.35) | PTGS2TDP1 | |
| SCHEMBL15046628 | 0.74 | PTGS2 (0.51) | PTGS2CREBBPALDH1A1 | |
| SCHEMBL505992 | 0.71 | PTGS2 (0.35) | PTGS2ALDH1A1LMNA | |
| SCHEMBL506213 | 0.71 | PTGS2 (0.45) | PTGS2ALDH1A1 | |
| SCHEMBL506014 | 0.70 | MEN1 (0.33) | PTGS2ALDH1A1 | |
| SCHEMBL31313713 | 0.70 | KDM4E (0.35) | TDP1FAAHMGLL | |
| SCHEMBL15046558 | 0.69 | PTGS2 (0.62) | PTGS2CREBBPALDH1A1LMNATDP1 | |
| SCHEMBL1852937 | 0.69 | PTGS2 (0.57) | PTGS2 | |
| SCHEMBL16064383 | 0.69 | KMT2A (0.36) | PTGS2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-119241424-A | Preparation method of 2- (difluoromethoxy) -5-bromopyridine | 浙江药领医药科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| US-20240360157-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | PTGS2 3989/4885CREBBP 508/4885ALDH1A1 4692/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | PTGS2 2866/4885CREBBP 2527/4885ALDH1A1 4708/4885 |
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | PTGS2 2134/4885CREBBP 1082/4885ALDH1A1 1242/4885 |
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | PTGS2 1703/4885CREBBP 3902/4885ALDH1A1 596/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | PTGS2 1604/4885CREBBP 1601/4885ALDH1A1 3756/4885 |
| US-20240360157-A1 | TYK2 INHIBITORS | TYK2, JAK2, ABL1 | PTGS2 2767/4885CREBBP 3008/4885ALDH1A1 4716/4885 |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | PTGS2 985/4885CREBBP 444/4885ALDH1A1 1591/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | PTGS2 3989/4885CREBBP 508/4885ALDH1A1 4692/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | PTGS2 3989/4885CREBBP 508/4885ALDH1A1 4692/4885 |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | PTGS2 1907/4885CREBBP 1131/4885ALDH1A1 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.